Cargando…

P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the Aurora-B Kinase Inhibitor barasertib-hQPA

BACKGROUND: Aurora kinases play an essential role in orchestrating chromosome alignment, segregation and cytokinesis during mitotic progression, with both aurora-A and B frequently over-expressed in a variety of human malignancies. Over-expression of the ABC drug transporter proteins P-glycoprotein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grundy, Martin, Seedhouse, Claire, Russell, Nigel H, Pallis, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146447/ https://www.ncbi.nlm.nih.gov/pubmed/21679421 http://dx.doi.org/10.1186/1471-2407-11-254

Ejemplares similares

Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
por: Pallis, Monica, et al.
Publicado: (2016)

Targeting of CD34(+)CD38(-) cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia
por: Jawad, Mays, et al.
Publicado: (2012)

Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
por: Dennis, Mike, et al.
Publicado: (2012)

Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells
por: Pallis, Monica, et al.
Publicado: (2013)

Structure of Aurora B–INCENP in complex with barasertib reveals a potential transinhibitory mechanism
por: Sessa, Fabio, et al.
Publicado: (2014)

A molecular signature of dormancy in CD34(+)CD38(-) acute myeloid leukaemia cells
por: Al-Asadi, Mazin Gh., et al.
Publicado: (2017)

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells
por: Grundy, Martin, et al.
Publicado: (2018)

Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial
por: Pallis, M, et al.
Publicado: (2011)

Barasertib: a novel approach for the treatment of metastatic melanoma
por: Azzariti, Amalia, et al.
Publicado: (2014)

Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling
por: Grundy, Martin, et al.
Publicado: (2018)

DNA damage corrects the aberrant cytoplasmic localisation of nucleophosmin in NPM1 mutated acute myeloid leukaemia
por: Bailey, Graham D., et al.
Publicado: (2019)

Phenotypically Dormant and Immature Leukaemia Cells Display Increased Ribosomal Protein S6 Phosphorylation
por: Pallis, Monica, et al.
Publicado: (2016)

Evolution of Resistance to Aurora Kinase B Inhibitors in Leukaemia Cells
por: Failes, Timothy W., et al.
Publicado: (2012)

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
por: Kelly, Kevin R, et al.
Publicado: (2011)

Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukaemia
por: Bailey, G. D., et al.
Publicado: (2020)

Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia
por: Moreira-Nunes, Caroline Aquino, et al.
Publicado: (2020)

SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis
por: Voisset, Edwige, et al.
Publicado: (2020)

Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review
por: Gavriilidis, Paschalis, et al.
Publicado: (2015)

Myeloid Leukæmia Treated by Deep X-Ray Therapy
por: Mallick, S. M. K., et al.
Publicado: (1938)

Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis
por: Liu, Jingjing, et al.
Publicado: (2020)

Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors
por: Nishiyama-Fujita, Yuriko, et al.
Publicado: (2022)

Aurora kinases in ovarian cancer
por: Pérez-Fidalgo, J Alejandro, et al.
Publicado: (2020)

Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells
por: Grundy, Martin, et al.
Publicado: (2018)

Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle
por: Hochegger, Helfrid, et al.
Publicado: (2013)

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor
por: Niu, Huifeng, et al.
Publicado: (2017)

Chemotherapy of the Myeloid Leukaemias
por: Stuart, John
Publicado: (1980)

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
por: Keizer, Ron J., et al.
Publicado: (2011)

Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target
por: Hartsink-Segers, S A, et al.
Publicado: (2013)

A Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy
por: Casey, Nicholas Paul, et al.
Publicado: (2016)

The Aurora Kinases in Cell Cycle and Leukemia
por: Goldenson, Benjamin, et al.
Publicado: (2014)

Ubiquitin-Mediated Degradation of Aurora Kinases
por: Lindon, Catherine, et al.
Publicado: (2016)

Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells
por: Kim, Soo-Jeong, et al.
Publicado: (2012)

Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
por: Ladikou, E. E., et al.
Publicado: (2020)

Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
por: Rychter, Anna, et al.
Publicado: (2017)

Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia
por: Lindström, H. Jonathan G., et al.
Publicado: (2019)

Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax
por: Maravalle, Denise, et al.
Publicado: (2022)

Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins
por: Carmena, Mar, et al.
Publicado: (2009)

Computational completion of the Aurora interaction region of N-Myc in the Aurora a kinase complex
por: Altiner, Pinar, et al.
Publicado: (2023)

Erythropoiesis in Murine Myeloid Leukaemia
por: Tanaka, T.
Publicado: (1970)

Desacetylmethylcolchicine in the Treatment of Myeloid Leukaemia
por: Jelliffe, A. M., et al.
Publicado: (1956)

Cannot write session to /tmp/vufind_sessions/sess_idknia2ted11730r8run8kpn0h